CeriBell, Inc.

CeriBell, Inc. is a medical technology company dedicated to transforming the diagnosis and management of patients with serious neurological conditions. Headquartered in Sunnyvale, California, the company's mission is to establish its proprietary Ceribell System as the standard of care for electroencephalography (EEG) in acute care settings, thereby assisting clinicians in improving patient outcomes.

Ceribell's core offering is the Ceribell System, a novel point-of-care EEG platform. This system integrates proprietary, portable hardware, including disposable headbands and a handheld recorder, with sophisticated artificial intelligence (AI)-powered algorithms, notably Clarity AI. The technology enables rapid diagnosis and continuous monitoring of neurological conditions, primarily in emergency departments and intensive care units. The system is FDA 510(k) cleared for indicating suspected seizure activity and has expanded its applications to include neonates, pediatric patients, and delirium monitoring. The company also provides an EEG Portal for remote access and review of patient data.

Led by co-founder and CEO Jane Chao, Ph.D., Ceribell became a publicly traded company in 2024. Recent developments include receiving FDA Breakthrough Device designation in January 2026 for its large vessel occlusion (LVO) stroke detection monitor and launching an FDA-cleared device for bedside diagnosis and delirium monitoring in June 2026. The company continues to reinforce the clinical utility of its Clarity AI algorithm, with a new critical care medicine publication in June 2026 highlighting its role in measuring seizure burden and its link to neurological outcomes.